TABLE 2.

Comparison of Clinical Outcomes Between the Control Group and the Treatment Group

Clinical Outcomes	Total (n = 129)	Control Group (n = 59)	Lopinavir/Ritonavir Group (n = 51)	Chloroquine Group (n = 19)	Control vs Lopinavir/Ritonavir		Control vs Chloroquine
					P1	OR1 (95% CI)	P2	OR2 (95% CI)
Fever duration, median (range), d	8 (5–10), n = 89	8 (6–11), n = 44	7.5 (4.8–9.3), n = 38	6 (4–9), n = 7	0.146	0.910 (0.802 to 1.033)	0.690	0.958 (0.778 to 1.181)
Time from illness onset to, median (range), d
Chest CT improvement	15 (13–19.3), n = 114	15.5 (11–20.8), n = 52	13 (15–19), n = 47	14 (12–20), n = 15	0.949	1.003 (0.92 to 1.084)	0.770	0.984 (0.886 to 1.093)
Negative nucleic acid conversion	23 (15–33.8), n = 119	21 (15–28.8), n = 59	23 (17–35.5), n = 45	16 (14–41), n = 15	0.285	1.018 (0.985 to 1.051)	0.839	1.004 (0.963–1.047)
Severe cases, n (%)	6 (4.7)	2 (3.4)	3 (5.9)	1 (5.3)	0.882	1.163 (0.158 to 8.568)	0.714	1.583 (0.136 to 18.5)
Changes of Ct value from day 1 to day 7, median (range)
N gene	9.0 (3.9–13.3), n = 44	5 (2–11), n = 19	7 (5.0–12.5), n = 13	8.0 (6.6–20.8), n = 12	0.228	0.918 (0.800 to 1.055)	0.055	0.895 (0.798 to 1.002)
ORF1ab gene	8.9 (3.0–13.4), n = 44	4 (2–8), n = 19	8.5 (5.4–13.5), n = 13	7.6 (4.5–21), n = 12	0.172	0.916 (0.808 to 1.039)	0.077	0.920 (0.838 to 1.009)